|
| Study | Sample size |
Design (sequence generation) | Baseline characteristics | Intervention | Duration | Outcome measures |
| (T/C) | TACE | Experimental CMs |
|
|
Ayi and Liu 2011 [8] | 108 (54/54) | Single centre, parallel group, unblinded RCT (unreported) | Mean age (range): 56 (28–77)
Disease stage: NA
Child-Pugh score: C
KPS: >60 | 5-FU, HCPT, LP | Ai Di injection
(60 L/d) | 56 ds | (1) TR (short-term effectiveness)
(2) Survival at 6/12/24 mons
(3) KPS (QoL increase)
(4) AE |
|
| Bao 2007 [9] | 54 (28/26) | Single centre, parallel group, unblinded RCT (unreported) | Mean age (range): 51 (25–68)
Disease stage: II, III
Child-Pugh score: A, B
KPS: NA | 5-FU, DDP, MMC, HCPT, EPI, LP, GSP | Kang Ai injection
(40–60 mL/d) | 1 mon | (1) TR (short-term effectiveness)
(2) AE |
|
|
Cao et al. 2005 [10] | 100 (50/50) | Single centre, parallel group, unblinded RCT (unreported) | Mean age (range): NA
Disease stage: NA
Child-Pugh score: A
KPS: NA | 5-FU, MMC, LP | Gan Fu Kang capsule
(1 capsule, t.i.d.) | 60–80 ds | (1) Survival at 6/12/24/36 mons |
|
| Chen and Ding 2007 [11] | 60 (32/28) | Single centre, parallel group, unblinded RCT (random number table) | Age range: 36–70
Disease stage: NA
Child-Pugh score: NA
KPS: >60 | 5-FU, MMC, OX, LP, GSP | Ai Di injection
(60 mL/d) | 42 ds | (1) TR (short-term effectiveness)
(2) KPS (QoL increase)
(3) AE |
|
| Dan et al. 2007 [12] | 70 (35/35) | Single centre, parallel group, unblinded RCT (sequence of admission) | Age range: 29–70
Disease stage: II, III, IV
Child-Pugh score: NA
KPS: NA | 5-FU, DDP, THP, LP | Fu Zheng Ping Gan Xiao Liu Tang
(1 dose/d) | 1–6 mons | (1) TR (short-term effectiveness)
(2) Survival at 6/12/18 mons
(3) KPS (QoL increase) |
|
| Deng et al. 2009 [13] | 40 (20/20) | Single centre, parallel group, unblinded RCT (unreported) | Mean age (range): 52 (26–66)
Disease stage: III, IV
Child-Pugh score: NA
KPS: ≥70 | THP, LP | Fu Fang Ku Shen injection (20 mL/d) | 2 mons | (1) TR (short-term effectiveness)
(2) KPS (QoL increase)
(3) AE |
|
| Dong et al. 2007 [14] | 65 (33/32) | Single centre, parallel group, unblinded RCT (unreported) | Mean age: 56.5
Disease stage: II, III, IV
Child-Pugh score: NA
KPS: ≥60 | 5-FU, DDP, THP, LP | Ai Di injection
(80–100 mL/d) | 56 ds | (1) TR (short-term effectiveness)
(2) KPS (QoL increase)
(3) AE |
|
| Dong et al. 2008 [15] | 133 (67/66) | Single centre, parallel group, unblinded RCT (unreported) | Mean age (range): 56 (28–77)
Disease stage: NA
Child-Pugh score: NA
KPS: >60 | 5-FU, THP, LP | Jing Long capsule
(1 g, t.i.d.) | 56 ds | (1) TR (short-term effectiveness)
(2) Survival at 6/12/24 mons
(3) KPS (QoL increase)
(4) AE |
|
| Han 2009 [16] | 48 (30/18) | Single centre, parallel group, unblinded RCT (unreported) | Mean age (range): 49.9 (32–70)
Disease stage: II, III
Child-Pugh score: NA
KPS: NA | ADM, MMC, CBDCA, LP, GSP | Blood-activating and stasis-resolving herbs
(NA) | NA | (1) TR (short-term effectiveness)
(2) KPS (QoL increase) |
|
| Hou and Lu 2009 [17] | 72 (36/36) | Single centre, parallel group, unblinded RCT (drawing of lots) | Age range: 34–72
Disease stage: NA
Child-Pugh score: NA
KPS: >70 | DDP, BLM-A5, GC, LP, GSP | CMs given according to CM syndrome differentiation
(1 dose/d) | 4 wks | (1) TR (short-term effectiveness)
(2) KPS (QoL increase)
(3) AE |
|
| Huang et al. 2002 [18] | 57 (30/27) | Multicentre, parallel group, unblinded RCT (unreported) | Mean age (range): 59.5
(35–70)
Disease stage: II, III
Child-Pugh score: NA
KPS: NA | 5-FU, MMC, HCPT, LP | Kang Lai Te injection (200 mL/d) plus Bai Hua She She Cao injection (30 mL/d) | 2–4 mons | (1) TR (short-term effectiveness)
(2) Survival at 12 mons
(3) AE |
|
Huang 2008
[19] | 50 (30/20) | Single centre, parallel group, unblinded RCT (unreported) | Mean age (range): NA
Disease stage: II, III
Child-Pugh score: NA
KPS: NA | 5-FU, DDP, MMC, HCPT, LP | Ci Dan capsule
(5 capsules, t.i.d.) | 4 mons | (1) TR (short-term effectiveness)
(2) Survival at 12 mons
(3) AE |
|
| Jia et al. 2003 [20] | 66 (34/32) | Single centre, parallel group, unblinded RCT (unreported) | Mean age (range): NA
Disease stage: T3-4N0M0
Child-Pugh score: NA
KPS: >60 | 5-FU, DDP, ADM, MMC, LP, GSP | Brucea javanica oil Injection (30 mL/d) | 2–4 mons | (1) TR (short-term effectiveness)
(2) AE |
|
Li et al. 2009
[21] | 64 (32/32) | Single centre, parallel group, unblinded RCT (unreported) | Mean age (range): NA
Disease stage: II, III
Child-Pugh score: NA
KPS: ≥60 | 5-FU, DDP, ADM, LP | Kang Lai Te capsule
(6 capsules, q.i.d.) | 42–63 ds | (1) TR (short-term effectiveness)
(2) AE |
|
| Li 2007 [22] | 36 (20/16) | Single centre, parallel group, unblinded RCT (unreported) | Mean age (range): 50.9 (32–70)
Disease stage: II, III
Child-Pugh score: NA
KPS: NA | MMC, THP, CBDCA, LP, GSP | CMs for fortifying the spleen and activating the blood (1 dose/d) | NA | (1) TR (short-term effectiveness)
(2) KPS (QoL increase) |
|
| Li and Fan 2008 [23] | 128 (64/64) | Single centre, parallel group, unblinded RCT (unreported) | Mean age (range): NA
Disease stage: NA
Child-Pugh score: NA
KPS: >70 | 5-FU, EPI, MMC, LP | Fu Zheng Kang Ai Tang
(1 dose/d) | 3 mons | (1) TR (short-term effectiveness)
(2) Survival at 6/12/24 mons
(3) AE |
|
| Liang et al. 2005 [24] | 68 (35/33) | Single centre, parallel group, unblinded RCT (unreported) | Age range: 29–70
Disease stage: II, III
Child-Pugh score: NA
KPS: NA | DDP, MMC, EPI, LP | Matrine injection
(150 mL/d) | 28 ds | (1) TR (short-term effectiveness)
(2) AE |
|
| Liang et al. 2008 [25] | 121 (64/57) | Single centre, parallel group, unblinded RCT (unreported) | Mean age (range): 44.8 (30–70)
Disease stage: II, III
Child-Pugh score: NA
KPS: ≥60 | 5-FU, ADM, MMC, CBDCA, LP | Ci Dan capsule (5 capsules, q.i.d.) | 2 mons | (1) TR (short-term effectiveness)
(2) Survival at 6/12 mons
(3) KPS (QoL increase) |
|
| Liang et al. 2005 [26] | 146 (75/71) | Single centre, parallel group, unblinded RCT (random number table) | Mean age (range): 50.7 (20–74)
Disease stage: III, IV
Child-Pugh score: A, B, C
KPS: NA | MMC, EPI, CBDCA, LP | Bu Zhong Yi Qi Tang
(1st–3rd month: 1 dose/d; 4th–6th month: 2 doses/w) | 6 mons | (1) TR (short-term effectiveness)
(2) Survival at 6/12/24/36 mons |
|
| Ling 2010 [27] | 128 (64/64) | Single centre, parallel group, unblinded RCT (unreported) | Age range: 39–62
Disease stage: II, III, IV
Child-Pugh score: NA
KPS: NA | 5-FU, DDP, EPI, LP | Xiao Liu Tang
(1 dose/d) | 2-3 mons | (1) TR (short-term effectiveness)
(2) KPS (QoL increase) |
|
| Liu et al. 2007 [28] | 70 (34/36) | Single centre, parallel group, unblinded RCT (shuffling envelops) | Mean age (range): 50.7 (28–67)
Disease stage: II, III
Child-Pugh score: NA
KPS: NA | 5-FU, DDP, ADM, MMC, HCPT, LP, GSP | Kang Ai injection
(40 mL/d) | 20 ds | (1) TR (short-term effectiveness)
(2) KPS (QoL increase)
(3) AE |
|
| Lu and He 2009 [29] | 48 (24/24) | Single centre, parallel group, unblinded RCT (unreported) | Age range: 28–68
Disease stage: II, III
Child-Pugh score: NA
KPS: NA | DDP, MMC, EPI, LP | Experience CMs formula
(NA) | 3–12 mons | (1) TR (short-term effectiveness)
(2) KPS (QoL increase) |
|
Lu et al. 2010
[30] | 60 (30/30) | Single centre, parallel group, unblinded RCT (stratified randomization) | Mean age: 49.4
Disease stage: II, III, IV
Child-Pugh score: NA
KPS: NA | DDP, ADM, MMC, LP | Yang Gan Kang Ai Wan
(9 g, t.i.d.) | 135–270 ds | (1) Survival at 6/12/18 mons |
|
| Lu et al. 2007 [31] | 63 (33/30) | Single centre, parallel group, unblinded RCT (unreported) | Age range: 18–71
Disease stage: II, III
Child-Pugh score: A, B, C
KPS: 50–90 | DDP, GC, LP | Kang Ai injection
(40 mL/d) | 40 ds | (1) TR (short-term effectiveness)
(2) KPS (QoL increase)
(3) AE |
|
| Meng 2008 [32] | 148 (75/73) | Single centre, parallel group, unblinded RCT (unreported) | Mean age: 56
Disease stage: II, III | 5-FU, THP, LP | Ai Di injection
(50 mL/d) | 28 ds | (1) TR (short-term effectiveness)
(2) Survival at 6/12/24 mons
(3) KPS (QoL increase)
(4) AE |
|
| Shi and Sun 2005 [33] | 50 (30/20) | Single centre, parallel group, unblinded RCT (unreported) | Mean age (range): 52.3 (37–65)
Disease stage: NA
Child-Pugh score: NA
KPS: NA | 5-FU, MMC, LP, GSP | Tan Re Qing injection
(40 mL/d) | ≥14 ds | (1) KPS (QoL increase) |
|
| Qiao 2010 [34] | 40 (20/20) | Single centre, parallel group, unblinded RCT (unreported) | Age range: 18–65
Disease stage: II, III
Child-Pugh score: NA
KPS: >50 | 5-FU, DDP, ADM, LP | Ai Tong Xiao granule
(1 pack/d) | 56 ds | (1) KPS (QoL increase)
(2) AE |
|
| Sun et al. 2002 [35] | 236 (118/118) | Single centre, parallel group, unblinded RCT (unreported) | Mean age (range): 51.4 (26–74)
Disease stage: NA
Child-Pugh score: NA
KPS: NA | MMC, EPI, CBDCA, LP | Hua Chan Su injection
(20 mL/d) | 1–24 Ks | (1) Survival at 12/24/36 mons
(2) AE |
|
| Tang et al. 2010 [36] | 50 (30/20) | Multicentre, parallel group, unblinded RCT (unreported) | Mean age: 54.1
Disease stage: II, III
Child-Pugh score: NA
KPS: >60 | ADM, MMC, LP, GSP | Fu Gan injection (20 mL/d) | 2 mons | (1) TR (short-term effectiveness)
(2) Survival at 6/12/24 mons
(3) KPS (QoL increase) |
|
| Tian et al. 2001 [37] | 43 (23/20) | Single centre, parallel group, unblinded RCT (unreported) | Mean age (range): 52.2 (23–73)
Disease stage: II, III
Child-Pugh score: NA
KPS: 60–80 | 5-FU, DDP, ADM, LP | Fu Zheng Jie Du Tang
(1 dose/d) | 18–88 ds | (1) TR (short-term effectiveness)
(2) KPS (QoL increase) |
|
| Tian 2006 [38] | 72 (36/36) | Single centre, parallel group, unblinded RCT (unreported) | Mean age (range): 53 (33–75)
Disease stage: NA
Child-Pugh score: NA
KPS: ≥70 | 5-FU, DDP, ADM, MMC, LP | Ai Yi Shu injection
(0.5 mg/d) | NA | (1) TR (short-term effectiveness)
(2) Survival at 6/12/18/24 mons
(3) KPS (QoL increase)
(4) AE |
|
| Wang et al. 2002 [39] | 95 (47/48) | Multicentre, parallel group, unblinded RCT (unreported) | Mean age (range): 50.5 (28–73)
Disease stage: NA
Child-Pugh score: NA
KPS: ≥60 | 5-FU, ADM, MMC, THP, HCPT, CBDCA, LP, GSP | 960 mixture
(NA) | 42–210 ds | (1) TR (short-term effectiveness)
(2) KPS (QoL increase)
(3) AE |
|
Wang and Cheng 2009
[40] | 57 (27/30) | Single centre, parallel group, unblinded RCT (unreported) | Mean age (range): 48 (30–65)
Disease stage: II, III
Child-Pugh score: NA
KPS: ≥70 | 5-FU, DDP, ADM, LP, GSP | Fu Fang Ku Shen injection
(20 mL/d) | ≥20 ds | (1) TR (short-term effectiveness)
(2) Survival at 12/24/36 mons
(3) KPS (QoL increase) |
|
| Wang and Yang 2002 [41] | 60 (30/30) | Single centre, parallel group, unblinded RCT (unreported) | Mean age: 55.7
Disease stage: II, III
Child-Pugh score: NA
KPS: >60 | ADM, DDP, MMC, LP | Gan Ji granule
(1 pack, b.i.d.) | 3-4 mons | (1) TR (short-term effectiveness)
(2) Survival at 6/12 mons |
|
| Wang et al. 2008 [42] | 86 (43/43) | Single centre, parallel group, unblinded RCT (unreported) | Mean age: 55.56
Disease stage: II, III
Child-Pugh score: NA
KPS: >60 | DDP, ADM, MMC, LP | Jian Pi Qing Gan He Ji
(200 mL, b.i.d.) | 2 mons | (1) TR (short-term effectiveness) |
|
| Wang et al. 2007 [43] | 43 (22/21) | Single centre, parallel group, unblinded RCT (random number table) | Mean age (range): 64 (35–78)
Disease stage: II, III
Child-Pugh score: NA
KPS: NA | ADM, MMC, CBDCA | Qi Shu Fang
(1 dose/d) | 56 ds | (1) TR (short-term effectiveness)
(2) KPS (QoL increase)
(3) AE |
|
| Wang 2008 [44] | 59 (30/29) | Single centre, parallel group, unblinded RCT (unreported) | Mean age (range): 61 (38–78)
Disease stage: NA
Child-Pugh score: NA
KPS: NA | 5-FU, ADM/EPI, MMC, LP, GSP | Experience CMs formula
(1 dose/d) | >2 mons | (1) TR (short-term effectiveness)
(2) KPS (QoL increase) |
|
| Weng et al. 2008 [45] | 96 (55/41) | Single centre, parallel group, unblinded RCT (unreported) | Age range: 28–76
Disease stage: NA
Child-Pugh score: A, B
KPS: NA | 5-FU, DDP, ADM, MMC, LP, GSP | Experience CMs formula plus CM patch
(NA) | NA | (1) TR (short-term effectiveness)
(2) Survival at 6/12/24/36/48/
60 mons
(3) KPS (QoL increase)
(4) AE |
|
| Wu et al. 2000 [46] | 80 (36/44) | Single centre, parallel group, unblinded RCT (unreported) | Mean age: 51.4
Disease stage: II, III
Child-Pugh score: NA
KPS: NA | 5-FU, DDP, MMC, LP, GSP | Hua Chan Su injection
(20 mL/d) | 20 ds | (1) TR (short-term effectiveness)
(2) Survival at 6/12 mons
(3) AE |
|
| Wu 1999 [47] | 25 (13/12) | Single centre, parallel group, unblinded RCT (unreported) | Mean age (range): 55.4 (38–69)
Disease stage: II
Child-Pugh score: NA
KPS: NA | 5-FU, DDP, MMC, LP | Yi Guan Jian Jia Wei
(NA) | 24 wks | (1) Survival at 36 mons |
|
| Wu et al. 2003 [48] | 60 (30/30) | Single centre, parallel group, unblinded RCT (unreported) | Mean age (range): 51.9 (28–72)
Disease stage: II, III | 5-FU, ADM (or DDP), MMC, LP, GSP | Hu Gan Ruan Jian Fang
(NA) | NA | (1) TR (short-term effectiveness)
(2) Survival at 6/12 mons |
|
| Xu et al. 2006 [49] | 57 (30/27) | Single centre, parallel group, unblinded RCT (sequence of admission) | Mean age (range): 52.3 (39–72)
Disease stage: NA
Child-Pugh score: NA
KPS: NA | 5-FU, MMC, HCPT, LP | Fu Zheng Jie Du Tang
(1 dose/d) | 2–4 mons | (1) TR (short-term effectiveness)
(2) Survival at 12 mons |
|
| Xu et al. 2007 [50] | 52 (32/20) | Single centre, parallel group, unblinded RCT (unreported) | Age range: 38–75
Disease stage: II, III
Child-Pugh score: NA
KPS: NA | 5-FU, DDP, THP, LP | Ai Di Injection
(50 mL/d) | 4 wks | (1) TR (short-term effectiveness)
(2) KPS (QoL increase)
(3) AE |
|
| Xu et al. 2007 [51] | 60 (40/20) | Single centre, parallel group, unblinded RCT (unreported) | Age range: 35–72
Disease stage: II, III
Child-Pugh score: NA
KPS: NA | 5-FU, DDP/OX, HCPT, LP | CMs for fortifying the spleen and resolving dampness and activating the blood and detoxifying
(1 dose/d) | 2 mons | (1) TR (short-term effectiveness)
(2) AE |
|
| Xue et al. 2002 [52] | 70 (34/36) | Single centre, parallel group, unblinded RCT (unreported) | Mean age (range): 51.3 (26–72)
Disease stage: III, IV
Child-Pugh score: NA
KPS: NA | 5-FU, DDP, ADM, MMC, LP | Si Jun Zi Tang
(1 dose/d) | NA | (1) TR (short-term effectiveness)
(2) Survival at 12/24/36 mons
(3) AE |
|
| Yang 2010 [53] | 50 (25/25) | Single centre, parallel group, unblinded RCT (unreported) | Mean age (range): 54 (31–74)
Disease stage: NA
Child-Pugh score: A, B
KPS: NA | 5-FU, DDP, ADM, EPI, LP | Lian Hua Qing Gan Yin
(1 dose/d) | NA | (1) Survival at 12/24 mons |
|
| Yang 2006 [54] | 62 (31/31) | Single centre, parallel group, unblinded RCT (unreported) | Age range: 27–68
Disease stage: NA
Child-Pugh score: NA
KPS: NA | 5-FU, DDP, EPI, LP, GSP | Ai Di injection
(50 mL/d) | >1 mon | (1) TR (short-term effectiveness)
(2) KPS (QoL increase)
(3) AE |
|
| Yang 2006 [55] | 50 (28/22) | Single centre, parallel group, unblinded RCT (unreported) | Mean age (range): 50.6 (26–75)
Disease stage: II, III, IV
Child-Pugh score: NA
KPS: >60 | 5-FU, DDP, MMC, THP, LP | Ai Di injection
(50 mL/d) | 32 ds | (1) TR (short-term effectiveness)
(2) AE |
|
Yi et al. 2008
[56] | 67 (36/31) | Single centre, parallel group, unblinded RCT (shuffling envelops) | Mean age (range): 53.9 (25–69)
Disease stage: II, III
Child-Pugh score: NA
KPS: >60 | 5-FU, ADM, HCPT, LP, GSP | Kang Ai injection
(40 mL/d) | 12 wks | (1) TR (short-term effectiveness)
(2) KPS (QoL increase)
(3) AE |
|
| Yu and Kang 2010 [57] | 96 (48/48) | Multicentre, parallel group, unblinded RCT (unreported) | Mean age (range): 53.1 (30–69)
Disease stage: II, III
Child-Pugh score: NA
KPS: NA | 5-FU, ADM, HCPT, LP, GSP | Fu Fang Ku Shen injection
(20 mL/d) | 45 ds | (1) TR (short-term effectiveness)
(2) KPS (QoL increase)
(3) AE |
|
| Yuan et al. 2010 [58] | 62 (31/31) | Multicentre, parallel group, unblinded RCT (unreported) | Mean age (range): NA
Disease stage: NA
Child-Pugh score: NA
KPS: NA | 5-FU, DDP, MMC, THP, LP, GSP | CMs for soothing the liver, fortifying the spleen, and tonifying the kidney
(NA) | 3 mons | (1) TR (short-term effectiveness)
(2) KPS (QoL increase) |
|
| Yuan and Yu 2005 [59] | 73 (35/38) | Single centre, parallel group, unblinded RCT (unreported) | Age range: 34–69
Disease stage: NA
Child-Pugh score: NA
KPS: >50 | 5-FU, DDP, MMC, HCPT | Ai Di injection
(50 L/d) | >20 ds | (1) TR (short-term effectiveness) |
|
| R. Q. Zhai and H. Y. Zhai 2010 [60] | 62 (32/30) | Single centre, parallel group, unblinded RCT (random number table) | Mean age (range): 55.3 (28–72)
Disease stage: III, IV
Child-Pugh score: NA
KPS: ≥50 | MMC, EPI, CBDCA, LP | Hu Gan Xiao Zheng Tang (1st–3rd month: 1 dose/d; 4th month: 1 dose/2 d) plus San Jie Xiao Tong Gao (plaster therapy; 1 dose/2 ds) | 4 mons | (1) TR (short-term effectiveness)
(2) Survival at 6/12/24/36 mons
(3) KPS (QoL increase)
(4) AE |
|
| Zhang et al. 2005 [61] | 224 (116/108) | Single centre, parallel group, unblinded RCT (unreported) | Mean age (range): 51.3 (29–76)
Disease stage: NA
Child-Pugh score: NA
KPS: NA | MMC, EPI, CBDCA, LP | Jing Long capsule
(4 capsules, t.i.d.) | ≥3 yrs | (1) TR (short-term effectiveness)
(2) Survival at 6/12/24/36 mons |
|
| Zhang et al. 2007 [62] | 60 (30/30) | Single centre, parallel group, unblinded RCT (unreported) | Mean age (range): 50 (24–75)
Disease stage: II, III
Child-Pugh score: NA
KPS: ≥60 | 5-FU, DDP, ADM, MMC, LP, GSP | Chai Shao Liu Jun Zi Tang
(1 dose/d) | >1 mon | (1) TR (short-term effectiveness)
(2) KPS (QoL increase)
(3) AE |
|
| Zhang et al. 2008 [63] | 61 (31/30) | Single centre, parallel group, unblinded RCT (stratified randomization) | Mean age (range): 50.2 (24–67)
Disease stage: II, III
Child-Pugh score: A, B, C
KPS: NA | 5-FU, MMC, THP, LP | CMs given according to CM syndrome differentiation
(1 dose/d) | ≥2 mons | (1) TR (short-term effectiveness)
(2) Survival at 6/12/18/24 mons
(3) KPS (QoL increase) |
|
| Zhang et al. 2008 [64] | 64 (31/33) | Single centre, parallel group, unblinded RCT (sequence of admission) | Age range: 39–73
Disease stage: II, III, IV
Child-Pugh score: NA
KPS: >60 | 5-FU, DDP, HCPT, OX, LP | Jian Pi Fu Gan Tang
(1 dose/d) | >2 mons | (1) TR (short-term effectiveness)
(2) Survival at 6/12/18 mons
(3) KPS (QoL increase) |
|
| Zhang et al. 2007 [65] | 112 (58/54) | Single centre, parallel group, unblinded RCT (random number table) | Mean age (range): 57.2 (18–70)
Disease stage: II
Child-Pugh score: NA
KPS: ≥50 | 5-FU, DDP, EPI, VDS | Gu Ben Yi Liu II
(NA) | ≥2 mons | (1) TR (short-term effectiveness)
(2) Survival at 6/12/24 mons
(3) KPS (QoL increase)
(4) AE |
|
| Zhang 2011 [66] | 49 (25/24) | Single centre, parallel group, unblinded RCT (unreported) | Mean age (range): 49.9 (33–71)
Disease stage: II, III
Child-Pugh score: NA
KPS: >60 | NA | Blood-activating and stasis-resolving herbs
(NA) | 2-3 mons | (1) TR (short-term effectiveness)
(2) KPS (QoL increase) |
|
| Zhang et al. 2000 [67] | 95 (50/45) | Multicentre, parallel group, unblinded RCT (unreported) | Age range: 29–60
Disease stage: II, III
Child-Pugh score: NA
KPS: NA | 5-FU, DDP/ADM, MMC, LP | CMs for soothing the liver and regulating Qi, fortifying the spleen and harmonizing the stomach, tonifying the liver and kidney, and softening hardness and dissipating binds (1 dose/d) | ≥2-3 mons | (1) TR (short-term effectiveness)
(2) Survival at 6/12/24 mons |
|
Zhao and Huang 2005
[68] | 60 (30/30) | Single centre, parallel group, unblinded RCT (unreported) | Age range: 38–72
Disease stage: II
Child-Pugh score: NA
KPS: NA | 5-FU, EPI, HCPT, LP | Can Qi capsule
(NA) | NA | (1) TR (short-term effectiveness)
(2) AE |
|
| Zhao et al. 2006 [69] | 94 (48/46) | Single centre, parallel group, unblinded RCT (sequence of admission) | Mean age (range): 52.8 (40–64)
Disease stage: II, III
Child-Pugh score: NA
KPS: >70 | 5-FU, DDP, ADM, HCPT, LP, GSP | Liu Jun Zi Tang
(1 dose/d) | 126–168 ds | (1) TR (short-term effectiveness)
(2) Survival at 12/24/36 mons |
|
| Zhou et al. 2002 [70] | 228 (118/110) | Single centre, parallel group, unblinded RCT (sequence of admission) | Age range: 28–72
Disease stage: II, III
Child-Pugh score: NA
KPS: NA | 5-FU, DDP, ADM, MMC, LP, GSP | Liu Jun Zi Tang
(1 dose/d) | NA | (1) Survival at 6/12/24/36 mons |
|
| Zhou et al. 2010 [71] | 64 (32/32) | Single centre, parallel group, unblinded RCT (unreported) | Mean age (range): 49.7 (22–70)
Disease stage: NA
Child-Pugh score: A, B
KPS: ≥60 | MMC, BLM-A5, LP, GSP | Kang Ai Fang
(1 dose/d) | 3 mons | (1) TR (short-term effectiveness)
(2) Survival at 12 mons
(3) KPS (QoL increase) |
|
| Zou 2004 [72] | 50 (25/25) | Single centre, parallel group, unblinded RCT (unreported) | Mean age: 41
Disease stage: II, III
Child-Pugh score: NA
KPS: NA | 5-FU, MMC, HCPT, LP | Fu Fang Ku Shen injection
(16 mL/d) | 40 ds | (1) TR (short-term effectiveness)
(2) AE |
|
